Table 2.
General characteristics of respondents.
| Variables | Accuracy (n) | Frequency |
|---|---|---|
| K1. The Mpox virus is not a new discovery. | 542 | 57.3 |
| K2. The Mpox virus circulates only among primates, including humans. | 516 | 54.5 |
| K3. In most cases, Mpox does not present with the symptoms of an uncomplicated influenza-like illness. | 430 | 45.5 |
| K4. Mpox infection is associated with typical skin lesions. | 766 | 81.0 |
| K5. Asymptomatic patients cannot transmit the Mpox virus to others. | 270 | 28.5 |
| K6. European cases of Mpox have been mostly travel-associated. | 522 | 55.2 |
| K7. Currently, there is no specific vaccine against Mpox approved. | 550 | 58.1 |
| K8. Currently, there is no specific drug against Mpox approved. | 500 | 52.9 |
| K9. Recipients of the smallpox vaccine may need further vaccination shots against Mpox. | 550 | 58.1 |
| K10. Mpox causes more severe illness in children than in adults. | 548 | 57.9 |
| K11. Mpox infection is associated with a high rate of systemic complications. | 558 | 59.0 |
| K12. The skin rash associated with Mpox is typically synchronous (in a pattern). | 536 | 56.7 |
| K13. Standard preventive measures are effective in preventing Mpox infection. | 592 | 62.6 |
| K14. Mpox can survive for several days on contaminated surfaces. | 544 | 57.5 |
| K15. Mode of transmission. | 546 | 57.7 |
| K16. The usual case-fatality ratio of Mpox. | 214 | 22.6 |
| Knowledge level | ||
| Poor | 160 | 16.9 |
| Average | 726 | 76.7 |
| Good | 60 | 6.3 |
Keys: Mpox: Monkeypox